A new era in the treatment of food allergy

Exploring New Frontiers in Food Allergy Management: Mechanisms, Efficacy, and Future Directions

The field of food allergy treatment has seen significant advancements in recent years, particularly with the approval of new therapies by the FDA. Historically, treatment options were limited, with Palforzia being the first approved therapy in 2020 for peanut allergies in children aged 1-18. However, its reception was lukewarm, and it did not significantly alter the treatment landscape. The approval of omalizumab in early 2024 marked a pivotal moment, as it is the first treatment applicable to all food allergies and is suitable for patients aged one year and older, including adults. This development is significant as it introduces the first biologic treatment for food allergies, potentially setting a new industry standard. Despite these advancements, there remains a need for further exploration into the mechanisms, efficacy, and cost-effectiveness of these treatments, as well as the development of additional biologics and therapeutics that could further benefit food-allergic patients.

This Research Topic aims to explore the emerging treatments for food allergies, focusing on their mechanisms of action and potential to improve patient outcomes. The objective is to review available mechanistic studies, including safety and efficacy data from preclinical and clinical trials, and to discuss the implications of these treatments on current healthcare practices. By examining the effectiveness and cost-effectiveness of these therapies, the research seeks to determine their potential for widespread adoption and impact on treatment paradigms. Ultimately, the goal is to understand how these new therapies could transform clinical practice and patient expectations over time.

To gather further insights into the evolving landscape of food allergy treatments, we welcome articles addressing, but not limited to, the following themes:

- Pharmaceutical-grade allergen doses for oral immunotherapy: promise, challenges, and controversies.
- Epicutaneous immunotherapy: promise, challenges, and controversies.
- The impact of omalizumab and other anti-IgE mAbs on treatment paradigms.
- The role and effectiveness of microbiome therapies.
- New oral immunotherapy (OIT) products for multi-allergic patients.
- Biologic therapies in the pipeline, including IgGenix food-specific IgE mAbs, mast cell-directed therapies, and tolerance-inducing nanoparticles.
- The future of personalized treatments in food allergy based on patient phenotype.
- Ongoing initiatives and opportunities for drug repurposing in food allergy.

Topic Editor Dale Umetsu is on the Scientific Advisory Board of IgGenix, Food Allergy Science Initiative, AllAdapt, consultant with ASLAN, Triveni, Apogee. Aimmune. Topic Editor Philippe Begin has been an investigator on studies sponsored by Novartis, Sanofi, Regeneron, DBV technologies and ALK, and has received honoraria from Novartis, Sanofi, DBV, ALK, Pfizer and Astra-Zeneca.